Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCADE phase 3 trial of HC-1119 versus enzalutamide in metastatic castration-resistant prostate cancer
NL-OMON55283Phase 3Recruiting
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing HC-1119 arm with Enzalutamide arm (2 arms). Primary endpoint: Overall response rate. Started Oct 2021; status: recruiting.
02
Drugs
deutenzalutamideenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON55283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55283.